About Forus
Leadership
Values
Latest News
INESSS Recommendation to Deny Reimbursement for Multiple Myeloma Treatment is a Global Outlier
In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations...
XPOVIO® Now Funded in PEI
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria: PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...
XPOVIO® Now Funded in Ontario, Newfoundland and Labrador, and New Brunswick
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria: Ontario: Exceptional Access Program | ontario.ca Newfoundland...
Contact Us
Mailing Address:
FORUS Therapeutics Inc.
200 North Service Road West, Suite 129
Oakville, Ontario, L6M 2Y1
Phone: 1-877-359-9595
Fax: 1-877-359-9590
Patient Support:
Phone: 1-833-4YOUPSP (1-833-496-8777)
Fax: 1-833-4YOUFAX (1-833-496-8329)
Product Support:
Phone: 1-866-542-7500
Fax: 1-866-542-1100
Do not use this form to report adverse events. Adverse events can be reported at 1-866-542-7500.